

# CLINICAL CANCER RESEARCH

# TABLE OF CONTENTS

## HIGHLIGHTS

**4833** Selected Articles from This Issue

## SPECIAL FEATURES

### CCR Translations

**4835** **Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint Blockade**

Valsamo Anagnostou and Jason J. Luke

See related article, p. 4893

**4838** **Multi-omics Uncovering Different Faces of Clear Cell Ovarian Cancer**

Stephanie Lheureux

See related article, p. 4947

**4840** **Time to Optimize Deescalation Strategies in Triple-Negative Breast Cancer?**

Priyanka Sharma

See related article, p. 4995

### CCR Drug Updates

**4843** **FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors**

Jaleh Fallah, Michael H. Brave, Chana Weinstock, Gautam U. Mehta, Diana Bradford, Haley Gittleman, Erik W. Bloomquist, Rosane Charlab, Salaheldin S. Hamed, Claudia P. Miller, Sarah E. Dorff, Wiley A. Chambers, Bronwyn D. Mixer, Jeannette Dinin, William F. Pierce, Tiffany K. Ricks, Shenghui Tang, Martha Donoghue, Richard Pazdur, Laleh Amiri-Kordestani, Amna Ibrahim, and Julia A. Beaver

## Review

**4849** **Facts and Hopes in Immunotherapy of Endometrial Cancer**

Juan A. Marín-Jiménez, Sandra García-Mulero, Xavier Matías-Guiu, and Josep M. Piulats

## Special Report

**4861** **Electronic Nicotine Delivery Systems: An Updated Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology**

Roy S. Herbst, Dorothy Hatsukami, Dana Acton, Meredith Giuliani, Allyn Moushey, Jonathan Phillips, Shimere Sherwood, Benjamin A. Toll, Kasisomayajula Viswanath, Nicholas J.H. Warren, Graham W. Warren, and Anthony J. Alberg

## CLINICAL TRIALS: TARGETED THERAPY

**4871** **Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors**

Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, Todd M. Bauer, Charles G. Drake, Jennifer H. Choe, Daniel J. George, Janet L. Karlix, Susanna Ulahannan, Kris F. Sachsenmeier, Deanna L. Russell, Ganesh Moorthy, Ben S. Sidders, Elizabeth A. Pilling, Huifang Chen, Maureen M. Hattersley, Mayukh Das, Rakesh Kumar, Gayle P. Pouliot, and Manish R. Patel

## CLINICAL TRIALS: IMMUNOTHERAPY

**4885** **A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial**

Peter Hillemanns, Agnieszka Denecke, Linn Woelber, Gerd Böhmer, Matthias Jentschke, Karoline W. Schjetne, Karsten M.H. Bruins Slot, and Agnete B. Fredriksen

## PRECISION MEDICINE AND IMAGING

**4893** **PD-1<sup>T</sup> TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC**

Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D. Schouten, Ferry Lalezari, Dennis Peters, Willemijn S.M.E. Theelen, Viktor H. Koelzer, Kirsten D. Mertz, Alfred Zippelius, Michel M. van den Heuvel, Annegien Broeks, John B.A.G. Haanen, Ton N. Schumacher, Gerrit A. Meijer, Egbert F. Smit, Kim Monkhorst, and Daniela S. Thommen

See related commentary, p. 4835

# TABLE OF CONTENTS

- 4907** **ImmunoPET Imaging with <sup>89</sup>Zr-Labeled Atezolizumab Enables *In Vivo* Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma**  
Aditi Mulgaonkar, Roy Elias, Layton Woolford, Bing Guan, Kien Nham, Payal Kapur, Alana Christie, Vanina T. Tcheuyap, Nirmish Singla, I. Alex Bowman, Christina Stevens, Guiyang Hao, James Brugarolas, and Xiankai Sun
- 4917** **SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in *De Novo* Metastatic Castration-Sensitive Prostate Cancer**  
Umang Swami, Ryon P. Graf, Roberto H. Nussenzveig, Virginia Fisher, Hanna Tukachinsky, Alexa B. Schrock, Gerald Li, Jeffrey S. Ross, Nicolas Sayegh, Nishita Tripathi, Vinay Mathew Thomas, Geoffrey R. Oxnard, Emmanuel S. Antonarakis, and Neeraj Agarwal
- 4926** **Family History of Prostate and Breast Cancer Integrated with a Polygenic Risk Score Identifies Men at Highest Risk of Dying from Prostate Cancer before Age 75 Years**  
Anna Plym, Yiwen Zhang, Konrad H. Stopsack, Yon Ho Jee, Fredrik Wiklund, Adam S. Kibel, Peter Kraft, Edward Giovannucci, Kathryn L. Penney, and Lorelei A. Mucci
- 4934** **Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors**  
David G.P. van IJzendoorn, Magdalena Matusiak, Gregory W. Charville, Geert Spierenburg, Sushama Varma, Deana R.C. Colburg, Michiel A.J. van de Sande, Kirsten van Langevelde, David G. Mohler, Kristen N. Ganjoo, Nam Q. Bui, Raffi S. Avedian, Judith V.M.G. Bovée, Robert Steffner, Robert B. West, and Matt van de Rijn
- 4947** **Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes**  
Kelly L. Bolton, Denise Chen, Rosario Corona de la Fuente, Zhuxuan Fu, Rajmohan Murali, Martin Köbel, Yanis Tazi, Julie M. Cunningham, Irena C.C. Chan, Brian J. Wiley, Lea A. Moukarzel, Stacey J. Winham, Sebastian M. Armasu, Jenny Lester, Esther Elishaev, Angela Laslavic, Catherine J. Kennedy, Anna Piskorz, Magdalena Sekowska, Alison H. Brand, Yoke-Eng Chiew, Paul Pharoah, Kevin M. Elias, Ronny Drapkin, Michael Churchman, Charlie Gourley, Anna DeFazio, Beth Karlan, James D. Brenton, Britta Weigelt, Michael S. Anglesio, David Huntsman, Simon Gayther, Jason Konner, Francesmary Modugno, Kate Lawrenson, Ellen L. Goode, and Elli Papaemmanuil  
**See related commentary, p. 4838**
- 4957** **Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates *CXCR4* mRNA Expression Levels to Potential Clinical Targets**  
Florian Kocher, Alberto Puccini, Gerold Untergasser, Agnieszka Martowicz, Kai Zimmer, Andreas Pircher, Yasmine Baca, Joanne Xiu, Johannes Haybaeck, Piotr Tymoszuk, Richard M. Goldberg, Angelica Petrillo, Anthony F. Shields, Mohamed E. Salem, John L. Marshall, Michael Hall, W. Michael Korn, Chadi Nabhan, Francesca Battaglin, Heinz-Josef Lenz, Emil Lou, Su-Pin Choo, Chee-Keong Toh, Silvia Gasteiger, Renate Pichler, Dominik Wolf, and Andreas Seiber
- 4968** **Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks**  
Anthony R. Cillo, Elina Mukherjee, Nathanael G. Bailey, Sayali Onkar, Jessica Daley, Claudia Salgado, Xiang Li, Dongyan Liu, Sarangarajan Ranganathan, Melissa Burgess, John Sembrat, Kurt Weiss, Rebecca Watters, Tullia C. Bruno, Dario A.A. Vignali, and Kelly M. Bailey
- 4983** **Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma**  
Nadine Benhamouda, Ikuan Sam, Nicolas Epailard, Alain Gey, Letuan Phan, Hang Phuong Pham, Nadège Gruel, Antonin Saldmann, Joséphine Pineau, Milena Hasan, Valentin Quiniou, Camille Nevoret, Virginie Verkarre, Valentina Libri, Sebastien Mella, Clémence Granier, Chloe Broudin, Patrice Ravel, Eléonore De Guillebon, Laetitia Mauge, Dominique Helley, Bernd Jabla, Nathalie Chaput, Laurence Albiges, Sandrine Katsahian, Julien Adam, Arnaud Mejean, Olivier Adotevi, Yann A. Vano, Stéphane Oudard, and Eric Tartour
- 4995** **De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial**  
Oleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, Alex Prat, Matthias Christgen, Sherko Kuemmel, Mohammad Parsa Mohammadian, Daniel Gebauer, Ronald Kates, Laia Paré, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Rachel Wuerstein, Monika Graeser, Enrico Pelz, Katarzyna Józwiak, Christine zu Eulenburg, Hans Heinrich Kreipe, and Nadia Harbeck; on behalf of the ADAPT TN investigators  
**See related commentary, p. 4840**

# TABLE OF CONTENTS

## ABOUT THE COVER

The cover shows an FFPE section of pancreatic ductal adenocarcinoma (PDAC, tumor cells in *cyan*). Opal multiplex immunofluorescence staining shows expression of the chemokine receptor CXCR4 (*yellow*) on tumor-infiltrating lymphocytes together with CD8<sup>+</sup> T cells (*green*) and macrophages (CD68, *red*). For details, see the article by Kocher and colleagues on page 4957 of this issue.

---

doi: 10.1158/1078-0432.CCR-28-22-CVR

